Cargando…

Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing

Human saphenous vein (hSV) and synthetic grafts are commonly used conduits in vascular grafting, despite high failure rates. Decellularising hSVs (D-hSVs) to produce vascular scaffolds might be an effective alternative. We assessed the effectiveness of a detergent-based method using 0% to 1% sodium...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulaiman, Nadiah S, Bond, Andrew R, Bruno, Vito D, Joseph, John, Johnson, Jason L, Suleiman, M-Saadeh, George, Sarah J, Ascione, Raimondo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010838/
https://www.ncbi.nlm.nih.gov/pubmed/33854749
http://dx.doi.org/10.1177/2041731420987529
_version_ 1783673137758470144
author Sulaiman, Nadiah S
Bond, Andrew R
Bruno, Vito D
Joseph, John
Johnson, Jason L
Suleiman, M-Saadeh
George, Sarah J
Ascione, Raimondo
author_facet Sulaiman, Nadiah S
Bond, Andrew R
Bruno, Vito D
Joseph, John
Johnson, Jason L
Suleiman, M-Saadeh
George, Sarah J
Ascione, Raimondo
author_sort Sulaiman, Nadiah S
collection PubMed
description Human saphenous vein (hSV) and synthetic grafts are commonly used conduits in vascular grafting, despite high failure rates. Decellularising hSVs (D-hSVs) to produce vascular scaffolds might be an effective alternative. We assessed the effectiveness of a detergent-based method using 0% to 1% sodium dodecyl sulphate (SDS) to decellularise hSV. Decellularisation effectiveness was measured in vitro by nuclear counting, DNA content, residual cell viability, extracellular matrix integrity and mechanical strength. Cytotoxicity was assessed on human and porcine cells. The most effective SDS concentration was used to prepare D-hSV grafts that underwent preliminary in vivo testing using a porcine carotid artery replacement model. Effective decellularisation was achieved with 0.01% SDS, and D-hSVs were biocompatible after seeding. In vivo xeno-transplantation confirmed excellent mechanical strength and biocompatibility with recruitment of host cells without mechanical failure, and a 50% patency rate at 4-weeks. We have developed a simple biocompatible methodology to effectively decellularise hSVs. This could enhance vascular tissue engineering toward future clinical applications.
format Online
Article
Text
id pubmed-8010838
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-80108382021-04-13 Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing Sulaiman, Nadiah S Bond, Andrew R Bruno, Vito D Joseph, John Johnson, Jason L Suleiman, M-Saadeh George, Sarah J Ascione, Raimondo J Tissue Eng Original Article Human saphenous vein (hSV) and synthetic grafts are commonly used conduits in vascular grafting, despite high failure rates. Decellularising hSVs (D-hSVs) to produce vascular scaffolds might be an effective alternative. We assessed the effectiveness of a detergent-based method using 0% to 1% sodium dodecyl sulphate (SDS) to decellularise hSV. Decellularisation effectiveness was measured in vitro by nuclear counting, DNA content, residual cell viability, extracellular matrix integrity and mechanical strength. Cytotoxicity was assessed on human and porcine cells. The most effective SDS concentration was used to prepare D-hSV grafts that underwent preliminary in vivo testing using a porcine carotid artery replacement model. Effective decellularisation was achieved with 0.01% SDS, and D-hSVs were biocompatible after seeding. In vivo xeno-transplantation confirmed excellent mechanical strength and biocompatibility with recruitment of host cells without mechanical failure, and a 50% patency rate at 4-weeks. We have developed a simple biocompatible methodology to effectively decellularise hSVs. This could enhance vascular tissue engineering toward future clinical applications. SAGE Publications 2021-03-29 /pmc/articles/PMC8010838/ /pubmed/33854749 http://dx.doi.org/10.1177/2041731420987529 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Sulaiman, Nadiah S
Bond, Andrew R
Bruno, Vito D
Joseph, John
Johnson, Jason L
Suleiman, M-Saadeh
George, Sarah J
Ascione, Raimondo
Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing
title Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing
title_full Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing
title_fullStr Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing
title_full_unstemmed Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing
title_short Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing
title_sort effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: bench optimisation and feasibility in vivo testing
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010838/
https://www.ncbi.nlm.nih.gov/pubmed/33854749
http://dx.doi.org/10.1177/2041731420987529
work_keys_str_mv AT sulaimannadiahs effectivedecellularisationofhumansaphenousveinsforbiocompatiblearterialtissueengineeringapplicationsbenchoptimisationandfeasibilityinvivotesting
AT bondandrewr effectivedecellularisationofhumansaphenousveinsforbiocompatiblearterialtissueengineeringapplicationsbenchoptimisationandfeasibilityinvivotesting
AT brunovitod effectivedecellularisationofhumansaphenousveinsforbiocompatiblearterialtissueengineeringapplicationsbenchoptimisationandfeasibilityinvivotesting
AT josephjohn effectivedecellularisationofhumansaphenousveinsforbiocompatiblearterialtissueengineeringapplicationsbenchoptimisationandfeasibilityinvivotesting
AT johnsonjasonl effectivedecellularisationofhumansaphenousveinsforbiocompatiblearterialtissueengineeringapplicationsbenchoptimisationandfeasibilityinvivotesting
AT suleimanmsaadeh effectivedecellularisationofhumansaphenousveinsforbiocompatiblearterialtissueengineeringapplicationsbenchoptimisationandfeasibilityinvivotesting
AT georgesarahj effectivedecellularisationofhumansaphenousveinsforbiocompatiblearterialtissueengineeringapplicationsbenchoptimisationandfeasibilityinvivotesting
AT ascioneraimondo effectivedecellularisationofhumansaphenousveinsforbiocompatiblearterialtissueengineeringapplicationsbenchoptimisationandfeasibilityinvivotesting